Hts-compatible patient-derived cell-based assay to identify small molecule modulators of aberrant splicing in myotonic dystrophy type 1

Current Chemical Genomics

Volumn 4, Issue 1, 2010, Pages 9-18

  O'Leary, Debra A ^a,b   Vargas, Leonardo ^a   Sharif, Orzala ^a   Garcia, Michael E ^a   Sigal, Yury J ^a   Chow, Siu Kei ^a   Schmedt, Christian ^a   Caldwell, Jeremy S ^c   Brinker, Achim ^a   Engels, Ingo H ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b DART NEUROSCIENCE LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alternative splicing; Cell based assay; Dm1; Hts; Myotonic dystrophy

Indexed keywords

CHLORIDE CHANNEL; CHLORIDE CHANNEL 1; MUSCLE PROTEIN; MUSCLEBLIND 1 PROTEIN; MYOD PROTEIN; MYOTONIC DYSTROPHY PROTEIN KINASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FIBROBLAST; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTRON; MYOBLAST; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; MYOTUBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 78249271398     PISSN: None     EISSN: 18753973     Source Type: Journal    
DOI: 10.2174/1875397301004010009     Document Type: Article

References (56)

1. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005; 32: 1-18.
2. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255: 1253-5.
3. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 69: 385.
4. Hunter A, Tsilfidis C, Mettler G, et al. The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet 1992; 29: 774-9.
5. Gharehbaghi-Schnell EB, Finsterer J, Korschineck I, Mamoli B, Binder BR. Genotype-phenotype correlation in myotonic dystrophy. Clin Genet 1998; 53: 20-6.
6. Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289: 1769-1773.
7. Reddy S, Smith DB, Rich MM, et al. Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet 1996; 13: 325-323.
8. Napierala M, Krzyzosiak WJ. CUG repeats present in myotonin kinase RNA form metastable slippery hairpins. J Biol Chem 1997; 272: 31079-31085.
9. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995; 128: 995-1002.
10. Furling D, Lam le T, Agbulut O, Butler-Browne GS, Morris GE. Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy. Am J Pathol 2003; 162: 1001-9.
11. Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006; 15: 2087-2097.
12. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280: 737-734.
13. Pascual M, Vicente M, Monferrer L, Artero R. The muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006; 74: 65-80.
14. Holt I, Jacquemin V, Fardaei M, et al. Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. Am J Pathol 2009; 174: 216-212.
15. Miller JW, Urbinati CR, Teng-Umnuay P, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 2000; 19: 4439-4448.
16. Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003; 302: 1978-1980.
17. Kanadia RN, Shin J, Yuan Y, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA 2006; 103: 11748-11753.
18. Ho TH, Bundman D, Armstrong DL, Cooper TA. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet 2005; 14: 1539-1547.
19. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117: 3952-7.
20. Mulders SA, van den Broek WJ, Wheeler TM, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 2009; 106: 13915-13920.
21. Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009; 325: 336-9.
22. Cooper TA. Molecular biology. Neutralizing toxic RNA. Science 2009; 325: 272-3.
23. Bender A, Bojanic D, Davies JW, et al. Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discov Devel 2008; 11: 327-323.
24. Moore K, Rees S. Cell-based versus isolated target screening: how lucky do you feel? J Biomol Screen 2001; 6: 69-74.
25. Soret J, Bakkour N, Maire S, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci USA 2005; 102: 8764-9.
26. Pushechnikov A, Lee MM, Childs-Disney JL, et al. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc 2009; 131: 9767-9779.
27. Kuyumcu-Martinez NM, Cooper TA. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol 2006; 44: 133-135.
28. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002; 10: 35-44.
29. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10: 45-53.
30. Koch MC, Ricker K, Otto M, et al. Evidence for genetic homogeneity in autosomal recessive generalised myotonia (Becker). J Med Genet 1993; 30: 914-7.
31. George AL, Jr., Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet 1993; 3: 305-301.
32. Markusic D, Oude-Elferink R, Das AT, Berkhout B, Seppen J. Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res 2005; 33: e63.
33. Shenoy AR, Visweswariah SS. Site-directed mutagenesis using a single mutagenic oligonucleotide and DpnI digestion of template DNA. Anal Biochem 2003; 319: 335-6.
34. Counter CM, Hahn WC, Wei W, et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci USA 1998; 95: 14723-8.
35. Mankodi A, Urbinati CR, Yuan QP, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10: 2165-2170.
36. Jansen G, Groenen PJ, Bachner D, et al. Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet 1996; 13: 316-312.
37. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA 2008; 105: 2646-2651.
38. Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 2007; 117: 2802-2811.
39. Lueck JD, Mankodi A, Swanson MS, Thornton CA, Dirksen RT. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 2007; 129: 79-94.
40. Mahadevan MS, Yadava RS, Yu Q, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006; 38: 1066-1070.
41. O'Cochlain DF, Perez-Terzic C, Reyes S, et al. Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy. Hum Mol Genet 2004; 13: 2505-2518.
42. Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, Timchenko LT. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 2004; 279: 13129-13139.
43. Iujvidin S, Fuchs O, Nudel U, Yaffe D. SV40 immortalizes myogenic cells: DNA synthesis and mitosis in differentiating myotubes. Differentiation 1990; 43: 192-203.
44. Tapscott SJ, Davis RL, Thayer MJ, Cheng PF, Weintraub H, Lassar AB. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 1988; 242: 405-401.
45. Amack JD, Reagan SR, Mahadevan MS. Mutant DMPK 3'-UTR transcripts disrupt C2C12 myogenic differentiation by compromising MyoD. J Cell Biol 2002; 159: 419-412.
46. Zhao XP, Pu CQ, Duan F, Liu JX, Mao YL, Luo P. MyoD mRNA expression in skeletal muscle of patients with myotonic dystrophy. Zhonghua Yi Xue Za Zhi 2009; 89: 466-8.
47. Carter RL, McCarthy KP, Machin LG, Jameson CF, Philp ER, Pinkerton CR. Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology 1989; 15: 585-589.
48. Andres V, Walsh K. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 1996; 132: 657-656.
49. Ma H, Urquidi V, Wong J, Kleeman J, Goodison S. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells. Mol Cancer Res 2003; 1: 739-734.
50. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276: 7820-6.
51. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steadystate levels of CUGBP1 in myotonic dystrophy 1 are due to PKCmediated hyperphosphorylation. Mol Cell 2007; 28: 68-78.
52. Watanabe T, Takagi A, Sasagawa N, Ishiura S, Nakase H. Altered expression of CUG binding protein 1 mRNA in myotonic dystrophy 1: possible RNA-RNA interaction. Neurosci Res 2004; 49: 47-54.
53. Cardani R, Mancinelli E, Rotondo G, Sansone V, Meola G. Muscleblind- like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Eur J Histochem 2006; 50: 177-178.
54. Bardouille C, Vullhorst D, Jockusch H. Expression of chloride channel 1 mRNA in cultured myogenic cells: a marker of myotube maturation. FEBS Lett 1996; 396: 177-178.
55. Logigian EL, Ciafaloni E, Quinn LC, et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007; 35: 479-478.
56. Salisbury E, Sakai K, Schoser B, et al. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res 2008; 314: 2266-2278.